These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 24312339)

  • 1. Mutational analysis of sclerostin shows importance of the flexible loop and the cystine-knot for Wnt-signaling inhibition.
    Boschert V; van Dinther M; Weidauer S; van Pee K; Muth EM; Ten Dijke P; Mueller TD
    PLoS One; 2013; 8(11):e81710. PubMed ID: 24312339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling.
    van Dinther M; Zhang J; Weidauer SE; Boschert V; Muth EM; Knappik A; de Gorter DJ; van Kasteren PB; Frisch C; Mueller TD; ten Dijke P
    PLoS One; 2013; 8(4):e62295. PubMed ID: 23638027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the interaction of sclerostin with the low density lipoprotein receptor-related protein (LRP) family of Wnt co-receptors.
    Holdsworth G; Slocombe P; Doyle C; Sweeney B; Veverka V; Le Riche K; Franklin RJ; Compson J; Brookings D; Turner J; Kennedy J; Garlish R; Shi J; Newnham L; McMillan D; Muzylak M; Carr MD; Henry AJ; Ceska T; Robinson MK
    J Biol Chem; 2012 Aug; 287(32):26464-77. PubMed ID: 22696217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.
    Ellies DL; Viviano B; McCarthy J; Rey JP; Itasaki N; Saunders S; Krumlauf R
    J Bone Miner Res; 2006 Nov; 21(11):1738-49. PubMed ID: 17002572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-deletion of Lrp5 and Lrp6 in the skeleton severely diminishes bone gain from sclerostin antibody administration.
    Lim KE; Bullock WA; Horan DJ; Williams BO; Warman ML; Robling AG
    Bone; 2021 Feb; 143():115708. PubMed ID: 33164872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.
    Li X; Zhang Y; Kang H; Liu W; Liu P; Zhang J; Harris SE; Wu D
    J Biol Chem; 2005 May; 280(20):19883-7. PubMed ID: 15778503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The sclerostin-neutralizing antibody AbD09097 recognizes an epitope adjacent to sclerostin's binding site for the Wnt co-receptor LRP6.
    Boschert V; Frisch C; Back JW; van Pee K; Weidauer SE; Muth EM; Schmieder P; Beerbaum M; Knappik A; Timmerman P; Mueller TD
    Open Biol; 2016 Aug; 6(8):. PubMed ID: 27558933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity.
    Chang MK; Kramer I; Keller H; Gooi JH; Collett C; Jenkins D; Ettenberg SA; Cong F; Halleux C; Kneissel M
    J Bone Miner Res; 2014 Jan; 29(1):29-42. PubMed ID: 23901037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies.
    Ettenberg SA; Charlat O; Daley MP; Liu S; Vincent KJ; Stuart DD; Schuller AG; Yuan J; Ospina B; Green J; Yu Q; Walsh R; Li S; Schmitz R; Heine H; Bilic S; Ostrom L; Mosher R; Hartlepp KF; Zhu Z; Fawell S; Yao YM; Stover D; Finan PM; Porter JA; Sellers WR; Klagge IM; Cong F
    Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15473-8. PubMed ID: 20713706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo.
    Choi HY; Dieckmann M; Herz J; Niemeier A
    PLoS One; 2009 Nov; 4(11):e7930. PubMed ID: 19936252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissecting molecular differences between Wnt coreceptors LRP5 and LRP6.
    MacDonald BT; Semenov MV; Huang H; He X
    PLoS One; 2011; 6(8):e23537. PubMed ID: 21887268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wnt antagonists bind through a short peptide to the first β-propeller domain of LRP5/6.
    Bourhis E; Wang W; Tam C; Hwang J; Zhang Y; Spittler D; Huang OW; Gong Y; Estevez A; Zilberleyb I; Rouge L; Chiu C; Wu Y; Costa M; Hannoush RN; Franke Y; Cochran AG
    Structure; 2011 Oct; 19(10):1433-42. PubMed ID: 21944579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sclerostin inhibits Wnt signaling through tandem interaction with two LRP6 ectodomains.
    Kim J; Han W; Park T; Kim EJ; Bang I; Lee HS; Jeong Y; Roh K; Kim J; Kim JS; Kang C; Seok C; Han JK; Choi HJ
    Nat Commun; 2020 Oct; 11(1):5357. PubMed ID: 33097721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystallization and preliminary X-ray crystallographic analysis of the sclerostin-neutralizing Fab AbD09097.
    Boschert V; Muth EM; Knappik A; Frisch C; Mueller TD
    Acta Crystallogr F Struct Biol Commun; 2015 Apr; 71(Pt 4):388-92. PubMed ID: 25849496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Competitive blocking of LRP4-sclerostin binding interface strongly promotes bone anabolic functions.
    Katchkovsky S; Chatterjee B; Abramovitch-Dahan CV; Papo N; Levaot N
    Cell Mol Life Sci; 2022 Jan; 79(2):113. PubMed ID: 35099616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesd is a universal inhibitor of Wnt coreceptors LRP5 and LRP6 and blocks Wnt/beta-catenin signaling in cancer cells.
    Lu W; Liu CC; Thottassery JV; Bu G; Li Y
    Biochemistry; 2010 Jun; 49(22):4635-43. PubMed ID: 20446724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome.
    Kedlaya R; Veera S; Horan DJ; Moss RE; Ayturk UM; Jacobsen CM; Bowen ME; Paszty C; Warman ML; Robling AG
    Sci Transl Med; 2013 Nov; 5(211):211ra158. PubMed ID: 24225945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reconstitution of a frizzled8.Wnt3a.LRP6 signaling complex reveals multiple Wnt and Dkk1 binding sites on LRP6.
    Bourhis E; Tam C; Franke Y; Bazan JF; Ernst J; Hwang J; Costa M; Cochran AG; Hannoush RN
    J Biol Chem; 2010 Mar; 285(12):9172-9. PubMed ID: 20093360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway.
    Lu W; Lin C; Roberts MJ; Waud WR; Piazza GA; Li Y
    PLoS One; 2011; 6(12):e29290. PubMed ID: 22195040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRP6 mediates Wnt/β-catenin signaling and regulates adipogenic differentiation in human mesenchymal stem cells.
    Peröbner I; Karow M; Jochum M; Neth P
    Int J Biochem Cell Biol; 2012 Nov; 44(11):1970-82. PubMed ID: 22871567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.